Hospira’s Global Quality Compliance Strategy Questioned In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter citing GMP violations at an Italian manufacturing site is another black mark for the sterile generic injectables maker, which is seeking to become among the handful of early biosimilar entrants in the U.S. market.
You may also be interested in...
Top FDA Compliance Official Notes 'Revival' Of Data Integrity Fraud
A top FDA compliance official warns the generic drug industry of a “revival” of data integrity fraud as a number of brand-name drugs go off patent and companies rush to be the first to file.
Pharma Pursues Generic Injectables Quality Turnaround Opportunities
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?
Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations
Revised draft guidance includes recommendations on preparing for FDA inspections, considerations for real-world data and digital health technologies, and the need for service level agreements between sponsors and IT providers.